The involvement of CD36 in monocyte activation by antiphospholipid antibodies

Lupus

Volumn 22, Issue 8, 2013, Pages 761-771

  Kato, M ^a   Atsumi, T ^a   Oku, K ^a   Amengual, O ^a   Nakagawa, H ^a   Fujieda, Y ^a   Otomo, K ^a   Horita, T ^a   Yasuda, S ^a   Koike, T ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Antiphospholipid syndrome; lupus anticoagulant; scavenger receptor; thrombosis

Indexed keywords

CARDIOLIPIN ANTIBODY; CD36 ANTIGEN; IMMUNOGLOBULIN G; INTERLEUKIN 6; LUPUS ANTICOAGULANT; PHOSPHATIDYLSERINE; PHOSPHOLIPID ANTIBODY; PROTHROMBIN ANTIBODY; THROMBOPLASTIN;

ADULT; AGED; ALLELE; ANTIPHOSPHOLIPID SYNDROME; ARTERY THROMBOSIS; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; FLOW CYTOMETRY; GENE FREQUENCY; GENOTYPE; HUMAN; HUMAN CELL; JAPANESE; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MONOCYTE; MONOCYTE ACTIVATION; PATHOGENESIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SYSTEMIC LUPUS ERYTHEMATOSUS; VEIN THROMBOSIS; WILD TYPE;

ANTIPHOSPHOLIPID SYNDROME; LUPUS ANTICOAGULANT; SCAVENGER RECEPTOR; THROMBOSIS;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIGENS, CD36; ANTIPHOSPHOLIPID SYNDROME; CASE-CONTROL STUDIES; FEMALE; FLOW CYTOMETRY; GENOTYPE; HUMANS; JAPAN; LUPUS ERYTHEMATOSUS, SYSTEMIC; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, KNOCKOUT; MIDDLE AGED; MONOCYTES; MUTATION, MISSENSE; POLYMERASE CHAIN REACTION; REAL-TIME POLYMERASE CHAIN REACTION; THROMBOPLASTIN; THROMBOSIS; YOUNG ADULT;

EID: 84879703668     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203313490242     Document Type: Article

References (49)

1. Atsumi T, Amengual O, Koike T Systemic lupus erythematosus. 5 th ed. Burlington, MA: Academic Press, 2011, pp. 945-966. Lahita RG Tsokos G Buyon J Koike T, ed. Burlington, MA: Academic Press ; 2011: 945-966.
2. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet. 1990 ; 336: 177-178
3. Sakai Y, Atsumi T, Ieko M, et al. The effects of phosphatidylserine- dependent antiprothrombin antibody on thrombin generation. Arthritis Rheum. 2009 ; 60: 2457-2467
4. Matsuura E, Igarashi Y, Yasuda T, Triplett DA, Koike T. Anticardiolipin antibodies recognize beta 2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med. 1994 ; 179: 457-462
5. Kornberg A, Blank M, Kaufman S, Shoenfeld Y. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol. 1994 ; 153: 1328-1332
6. Amengual O, Atsumi T, Khamashta MA, Hughes GR. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb Haemost. 1998 ; 79: 276-281
7. Bohgaki M, Atsumi T, Yamashita Y, et al. The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-beta2Glycoprotein I antibodies. Int Immunol. 2004 ; 16: 1633-1641
8. Vega-Ostertag M, Casper K, Swerlick R, Ferrara D, Harris EN, Pierangeli SS. Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. Arthritis Rheum. 2005 ; 52: 1545-1554
9. Lutters BC, Derksen RH, Tekelenburg WL, Lenting PJ, Arnout J, de Groot PG. Dimers of beta 2-glycoprotein I increase platelet deposition to collagen via interaction with phospholipids and the apolipoprotein E receptor 2'. J Biol Chem. 2003 ; 278: 33831-33838
10. Pennings MT, van Lummel M, Derksen RH, et al. Interaction of beta2-glycoprotein I with members of the low density lipoprotein receptor family. J Thromb Haemost. 2006 ; 4: 1680-1690
11. Pierangeli SS, Vega-Ostertag ME, Raschi E, et al. Toll-like receptor and antiphospholipid mediated thrombosis: In vivo studies. Ann Rheum Dis. 2007 ; 66: 1327-1333
12. Romay-Penabad Z, Montiel-Manzano MG, Shilagard T, et al. Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo. Blood. 2009 ; 114: 3074-3083
13. Satta N, Dunoyer-Geindre S, Reber G, et al. The role of TLR2 in the inflammatory activation of mouse fibroblasts by human antiphospholipid antibodies. Blood. 2007 ; 109: 1507-1514
14. Urbanus RT, Pennings MT, Derksen RH, de Groot PG. Platelet activation by dimeric beta2-glycoprotein I requires signaling via both glycoprotein Ibalpha and apolipoprotein E receptor 2'. J Thromb Haemost. 2008 ; 6: 1405-1412
15. Bohgaki M, Matsumoto M, Atsumi T, et al. Plasma gelsolin facilitates interaction between beta(2) glycoprotein I and alpha5beta1 integrin. J Cell Mol Med. 2011 ; 15: 141-151
16. Allen KL, Fonseca FV, Betapudi V, Willard B, Zhang J, McCrae KR. A novel pathway for human endothelial cell activation by antiphospholipid/anti-beta2 glycoprotein I antibodies. Blood. 2012 ; 119: 884-893
17. Febbraio M, Hajjar DP, Silverstein RL. CD36: A class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest. 2001 ; 108: 785-791
18. Podrez EA, Byzova TV, Febbraio M, et al. Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype. Nat Med. 2007 ; 13: 1086-1095
19. Febbraio M, Podrez EA, Smith JD, et al. Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest. 2000 ; 105: 1049-1056
20. Tomiyama Y, Take H, Ikeda H, et al. Identification of the platelet-specific alloantigen, Naka, on platelet membrane glycoprotein IV. Blood. 1990 ; 75: 684-687
21. Yanai H, Chiba H, Fujiwara H, et al. Phenotype-genotype correlation in CD36 deficiency types I and II. Thromb Haemost. 2000 ; 84: 436-441
22. Simsek S, Faber NM, Bleeker PM, et al. Determination of human platelet antigen frequencies in the Dutch population by immunophenotyping and DNA (allele-specific restriction enzyme) analysis. Blood. 1993 ; 81: 835-840
23. Curtis BR, Aster RH. Incidence of the Nak(a)-negative platelet phenotype in African Americans is similar to that of Asians. Transfusion. 1996 ; 36: 331-334
24. Yamamoto N, Akamatsu N, Sakuraba H, Yamazaki H, Tanoue K. Platelet glycoprotein IV (CD36) deficiency is associated with the absence (type I) or the presence (type II) of glycoprotein IV on monocytes. Blood. 1994 ; 83: 392-397
25. Aitman TJ, Cooper LD, Norsworthy PJ, et al. Malaria susceptibility and CD36 mutation. Nature. 2000 ; 405: 1015-1016
26. Okamoto F, Tanaka T, Sohmiya K, Kawamura K. CD36 abnormality and impaired myocardial long-chain fatty acid uptake in patients with hypertrophic cardiomyopathy. Jpn Circ J. 1998 ; 62: 499-504
27. Pravenec M, Churchill PC, Churchill MC, et al. Identification of renal Cd36 as a determinant of blood pressure and risk for hypertension. Nat Genet. 2008 ; 40: 952-954
28. Masuda D, Hirano K, Oku H, et al. Chylomicron remnants are increased in the postprandial state in CD36 deficiency. J Lipid Res. 2009 ; 50: 999-1011
29. Ghosh A, Li W, Febbraio M, et al. Platelet CD36 mediates interactions with endothelial cell-derived microparticles and contributes to thrombosis in mice. J Clin Invest. 2008 ; 118: 1934-1943
30. Cho S, Park EM, Febbraio M, et al. The class B scavenger receptor CD36 mediates free radical production and tissue injury in cerebral ischemia. J Neurosci. 2005 ; 25: 2504-2512
31. Hoebe K, Georgel P, Rutschmann S, et al. CD36 is a sensor of diacylglycerides. Nature. 2005 ; 433: 523-527
32. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 ; 4: 295-306
33. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 ; 40: 1725-1725
34. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: An update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost. 1995 ; 74: 1185-1190
35. Harris EN, Gharavi AE, Patel SP, Hughes GR. Evaluation of the anti-cardiolipin antibody test: Report of an international workshop held 4 April 1986. Clin Exp Immunol. 1987 ; 68: 215-222
36. Amengual O, Atsumi T, Khamashta MA, Koike T, Hughes GR. Specificity of ELISA for antibody to beta 2-glycoprotein I in patients with antiphospholipid syndrome. Br J Rheumatol. 1996 ; 35: 1239-1243
37. Atsumi T, Ieko M, Bertolaccini ML, et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum. 2000 ; 43: 1982-1993
38. Moore KJ, El Khoury J, Medeiros LA, et al. A CD36-initiated signaling cascade mediates inflammatory effects of beta-amyloid. J Biol Chem. 2002 ; 277: 47373-47379
39. Kopprasch S, Pietzsch J, Westendorf T, Kruse HJ, Grassler J. The pivotal role of scavenger receptor CD36 and phagocyte-derived oxidants in oxidized low density lipoprotein-induced adhesion to endothelial cells. Int J Biochem Cell Biol. 2004 ; 36: 460-471
40. Triantafilou M, Gamper FG, Haston RM, et al. Membrane sorting of toll-like receptor (TLR)-2/6 and TLR2/1 heterodimers at the cell surface determines heterotypic associations with CD36 and intracellular targeting. J Biol Chem. 2006 ; 281: 31002-31011
41. Bamberger ME, Harris ME, McDonald DR, Husemann J, Landreth GE. A cell surface receptor complex for fibrillar beta-amyloid mediates microglial activation. J Neurosci. 2003 ; 23: 2665-2674
42. Miao WM, Vasile E, Lane WS, Lawler J. CD36 associates with CD9 and integrins on human blood platelets. Blood. 2001 ; 97: 1689-1696
43. Atsumi T, Khamashta MA, Amengual O, Hughes GR. Up-regulated tissue factor expression in antiphospholipid syndrome. Thromb Haemost. 1997 ; 77: 222-223
44. Sorice M, Longo A, Capozzi A, et al. Anti-beta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum. 2007 ; 56: 2687-2697
45. Cervera R, Khamashta MA, Shoenfeld Y, et al. Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: A multicentre prospective study of 1000 patients. Ann Rheum Dis. 2009 ; 68: 1428-1432
46. Fischetti F, Durigutto P, Pellis V, et al. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood. 2005 ; 106: 2340-2346
47. Silverstein RL, Febbraio M. CD36, a scavenger receptor involved in immunity, metabolism, angiogenesis, and behavior. Sci Signal. 2009 ; 2: re3 - re3
48. Han J, Zhou X, Yokoyama T, Hajjar DP, Gotto AM, Nicholson AC. Pitavastatin downregulates expression of the macrophage type B scavenger receptor, CD36. Circulation. 2004 ; 109: 790-796
49. Yun MR, Park HM, Seo KW, Kim CE, Yoon JW, Kim CD. Cilostazol attenuates 4-hydroxynonenal-enhanced CD36 expression on murine macrophages via inhibition of NADPH oxidase-derived reactive oxygen species production. Korean J Physiol Pharmacol. 2009 ; 13: 99-106